Primary resistance to dopamine agonists occurs in 10–15% of prolactinomas but secondary
resistance following initial biochemical and anti-proliferative response is very rare and has …

OBJECTIVE: Dopamine agonists are the first line therapy for the treatment of prolactinomas.
The aim of this study was to assess the outcome of macroprolactinomas during long-term …

Resistance to dopamine agonists can be defined with respect to failure to normalize PRL
levels and failure to decrease tumor size by≥ 50%. Using these definitions, failure to …

The medical management of pituitary tumors is entering a new era. Novel compounds that
directly target the pituitary tumor have shown promise in patients with treatment-refractory or …

Objective Prolactinomas are the most common functional pituitary tumour. Dopamine
agonists (DA) are its principal treatment. The criteria that should guide therapy withdrawal …

Prolactinomas, the most prevalent type of neuroendocrine disease, account for
approximately 40% of all pituitary adenomas. The most important clinical problems …

Objective: Prolactinomas are primarily treated with medical therapy. Given the efficacy of
dopamine agonists (DAs), surgery has remained a second-line treatment option. Despite …

Prevalence and incidence of prolactinomas are approximately 50 per 100,000 and 3–5 new
cases/100,000/year. The pathophysiological mechanism of hyperprolactinemia-induced …

The discovery of dopamine inhibitory effects on prolactin secretion has led to an era of
successful dopaminergic therapy for prolactinomas. Herein we provide an overview of the …

Simple Summary This review updates recent advances in the pathogenesis, diagnosis, and
therapy of prolactinoma. Prolactinomas, comprising 30–50% of all pituitary neuroendocrine …